Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats
- 384 Downloads
The noncompetitive NMDA antagonist ketamine produces rapid antidepressant effects in treatment-resistant patients suffering from major depressive and bipolar disorders. However, abuse liability is a concern.
This study examined abuse-related effects of ketamine using intracranial self-stimulation (ICSS) in rats. The higher-affinity NMDA antagonist MK-801 and the monoamine reuptake inhibitor cocaine were examined for comparison.
Male Sprague Dawley rats were implanted with electrodes targeting the medial forebrain bundle and trained to respond to brain stimulation under a frequency–rate ICSS procedure. The first experiment compared the potency and time course of ketamine (3.2–10.0 mg/kg) and MK-801 (0.032–0.32 mg/kg). The second experiment examined effects of repeated dosing with ketamine (3.2–20.0 mg/kg/day) and acute cocaine (10.0 mg/kg).
Following acute administration, ketamine (3.2–10 mg/kg) produced only dose- and time-dependent depressions of ICSS and failed to produce an abuse-related facilitation of ICSS at any dose or pretreatment time. In contrast, MK-801 (0.032–0.32 mg/kg) produced a mixed profile of rate-increasing and rate-decreasing effects; ICSS facilitation was especially prominent at an intermediate dose of 0.18 mg/kg. Repeated dosing with ketamine produced dose-dependent tolerance to the rate-decreasing effects of ketamine (10.0 and 18.0 mg/kg) but failed to unmask expression of ICSS facilitation. Termination of ketamine treatment failed to produce withdrawal-associated decreases in ICSS. As reported previously, 10.0 mg/kg cocaine facilitated ICSS.
The dissociable effects of ketamine and MK-801 suggest differences in the pharmacology of these nominally similar NMDA antagonists. Failure of ketamine to facilitate ICSS contrasts with other evidence for the abuse liability of ketamine.
KeywordsKetamine MK-801 Intracranial self-stimulation Depression Bipolar Cocaine Rats
- Ardayfio PA, Benvenga MJ, Chaney SF, Love PL, Catlow J, Swanson SP, Marek GJ (2008) The 5-hydroxytryptamine2a receptor antagonist R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. J Pharmacol Exp Ther 327:891–897PubMedCrossRefGoogle Scholar
- Bonano JS, Glennon RA, De Felice LJ, Banks ML, Negus SS (2013) Abuse-related and abuse-limiting effects of methcathinone and the synthetic “bath salts” cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology. doi:10.1007/s00213-013-3223-5 PubMedGoogle Scholar
- de la Peña JBI, Lee HC, de la Peña IC, Woo TS, Yoon SY, Lee HL et al (2012) Rewarding and reinforcing effects of the NMDA receptor antagonist—benzodiazepine combination, Zoletil®: difference between acute and repeated exposure. Behav Brain Res 233:434–442. doi:10.1016/j.bbr.2012.05.038 PubMedCrossRefGoogle Scholar
- Gilmour G, Pioli E, Dix S, Smith J, Conway M, Jones W, Loomis S, Mason R, Shahabi S, Tricklebank M (2009) Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for “NMDA antagonist modelling” of schizophrenia. Psychopharmacology (Berl) 205:203–216CrossRefGoogle Scholar
- Institute of Laboratory Animal Resources (2011) Guide for the care and use of laboratory animals. 8th ed. Institute of Laboratory Animals Resources, Commission of Life Sciences, National Research Council, Washington DCGoogle Scholar
- Kenny PJ, Gasparini F, Markou A (2003) Group II metabotropic and α-Amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther 306:1068–1076PubMedCrossRefGoogle Scholar
- Lepore M, Liu X, Savage V, Matalon D, Gardner EL (1996) Genetic differences in Δ9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sci 58:365–372CrossRefGoogle Scholar
- Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aan Het Rot M et al (2012) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74:250–256. doi:10.1016/j.biopsych.2012.06.022 PubMedCentralPubMedCrossRefGoogle Scholar
- Réus GZ, Stringari RB, Ribeiro KF, Ferraro AK, Vitto MF, Cesconetto P, Souza CT, Quevedo J (2011) Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav Brain Res 221:166–171PubMedCrossRefGoogle Scholar
- Substance Abuse and Mental Health Services Administration (2013) Results from the 2012 National Survey on Drug Use and Health: summary of national findings, NSDUH Series H-46, HHS Publication No. (SMA) 13–4795. Rockville, MD: Substance Abuse and Mental Health Services AdministrationGoogle Scholar
- Wise RA (1996) Addictive drugs and brain stimulation reward. Annual Review of Neuroscience 19:319–340Google Scholar